A carregar...
The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy
Approximately 90% of patients with the hematological malignancies termed the chronic myeloproliferative neoplasms harbor either the JAK2V617F-mutation or CALR exon 9 mutation. Both of these are recognized by T-cells, which make the mutations ideal targets for cancer immune therapy as they are shared...
Na minha lista:
| Publicado no: | Oncoimmunology |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5674967/ https://ncbi.nlm.nih.gov/pubmed/29147619 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1358334 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|